These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

50 related articles for article (PubMed ID: 3619468)

  • 21. Suppression of natural killer cell cytotoxicity in the peripheral blood of patients receiving interferon therapy.
    Spina CA; Fahey JL; Durkos-Smith D; Dorey F; Sarna G
    J Biol Response Mod; 1983; 2(5):458-69. PubMed ID: 6644350
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Effects of alpha-interferon on MHC unrestricted cytotoxicity in chronic myelogenous leukemia.
    Meseri-Delwail A; Delwail V; Brizard A; Goube de Laforest P; Guilhot F; Lecron JC
    Biotechnol Ther; 1994; 5(1-2):47-57. PubMed ID: 7703832
    [TBL] [Abstract][Full Text] [Related]  

  • 23. [Effect of interferon on cell populations enriched in NK activity].
    Launay M; Genetet B; Ruffault A; Fauconnier B
    C R Seances Soc Biol Fil; 1983; 177(2):217-22. PubMed ID: 6224541
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Natural killer cell activity in patients with multiple sclerosis given alpha interferon.
    Rice GP; Casali P; Merigan TC; Oldstone MB
    Ann Neurol; 1983 Sep; 14(3):333-8. PubMed ID: 6638954
    [TBL] [Abstract][Full Text] [Related]  

  • 25. [Comparison of the effects of interferon of various types on the cytotoxic activity of NK cells].
    Dozono H; Terashima Y; Saijo N
    Gan No Rinsho; 1986 Oct; 32(12):1557-60. PubMed ID: 3783981
    [TBL] [Abstract][Full Text] [Related]  

  • 26. High-dose systemic interleukin-2 therapy in stage IV neuroblastoma for one year after autologous bone marrow transplantation: pilot study.
    Pardo N; Martí F; Fraga G; Illa J; Badell I; Peiró M; Bertran E; García J; Rueda F; Cubells J
    Med Pediatr Oncol; 1996 Dec; 27(6):534-9. PubMed ID: 8888813
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Murine strain variation in the natural killer cell and proliferative responses to the immunostimulatory compound 7-allyl-8-oxoguanosine: role of cytokines.
    Pope BL; Chourmouzis E; MacIntyre JP; Lee S; Goodman MG
    Cell Immunol; 1994 Dec; 159(2):194-210. PubMed ID: 7994754
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Characterization of natural killer and natural killer-like T cells derived from ex vivo expanded and activated cord blood mononuclear cells: implications for adoptive cellular immunotherapy.
    Ayello J; van de Ven C; Cairo E; Hochberg J; Baxi L; Satwani P; Cairo MS
    Exp Hematol; 2009 Oct; 37(10):1216-29. PubMed ID: 19638292
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Effect of interferon-alpha (MOR-22) on human NK cell activity].
    Yanagihara Y; Tochizawa S; Ishii K; Hirai Y
    Gan To Kagaku Ryoho; 1986 Feb; 13(2):342-8. PubMed ID: 3947110
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Differential effects of interferon-alpha 2 and interleukin-2 on natural killer cell activity in patients with acquired immune deficiency syndrome.
    Reddy MM; Chinoy P; Grieco MH
    J Biol Response Mod; 1984 Aug; 3(4):379-86. PubMed ID: 6332880
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Interferon-induced enhancement of newborn pig natural killing (NK) activity.
    Charley B; Petit E; La Bonnardière C
    Ann Rech Vet; 1985; 16(4):399-402. PubMed ID: 4091496
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Immunotherapy with autologous dendritic cells and tumor antigens for children with refractory malignant solid tumors.
    Suminoe A; Matsuzaki A; Hattori H; Koga Y; Hara T
    Pediatr Transplant; 2009 Sep; 13(6):746-53. PubMed ID: 19067917
    [TBL] [Abstract][Full Text] [Related]  

  • 33. NXS2 murine neuroblastomas express increased levels of MHC class I antigens upon recurrence following NK-dependent immunotherapy.
    Neal ZC; Imboden M; Rakhmilevich AL; Kim KM; Hank JA; Surfus J; Dixon JR; Lode HN; Reisfeld RA; Gillies SD; Sondel PM
    Cancer Immunol Immunother; 2004 Jan; 53(1):41-52. PubMed ID: 14504825
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Human peripheral blood monocytes are susceptible to interferon-activated natural killer cells.
    Einhorn S; Anderbring E
    J Clin Lab Immunol; 1985 Apr; 16(4):197-9. PubMed ID: 4020850
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Natural killer activity in respiratory papillomatosis and its changes after interferon treatment].
    Pritsker AD; Grigorian SS; Onufrieva EK; Chireshkin DG; Ershov FI
    Vopr Virusol; 1991; 36(5):409-11. PubMed ID: 1803776
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Natural killer cell function in cancer patients treated with natural leukocyte interferon-alpha.
    Ching C; Wong C; Cruz MV; Sato D; Wong GK; Herberman R; Ching N
    Hawaii Med J; 1986 Nov; 45(11):394-8, 408. PubMed ID: 3593472
    [No Abstract]   [Full Text] [Related]  

  • 37. Alpha interferon in myelodysplasia.
    Galvani DW
    Haematol Blood Transfus; 1989; 32():139-40. PubMed ID: 2625240
    [No Abstract]   [Full Text] [Related]  

  • 38. Treatment of myelodysplasia with alpha-interferon.
    Galvani D; Nethersell A; Bottomley J
    Leukemia; 1987 Nov; 1(11):786-7. PubMed ID: 3479666
    [No Abstract]   [Full Text] [Related]  

  • 39. The use of three baseline values in intervention studies: application to evaluation of immune modulation therapies.
    Korn EL; Dorey F; Spina CA; Fahey JL
    Immunobiology; 1984 Dec; 167(5):431-6. PubMed ID: 6526422
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Enhancement of NK-activity and LAK-activity in combination therapy with interferon-alpha in a child with neuroblastoma].
    Fukushima K; Tanaka K; Matsumoto Y; Nishikawa K; Hoshika T; Kohno Y; Okada T; Shiraki K
    Gan To Kagaku Ryoho; 1987 Aug; 14(8):2597-9. PubMed ID: 3619468
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 3.